← BioTransfer GEO Dataset Finder
GEO series

Identification of PRMT5 as a therapeutic target in cholangiocarcinoma [RNA-seq I]

GSE270017 Homo sapiens Expression profiling by high throughput sequencing 6 samples Submitted 2025/06/17 Platform GPL30173
Summary
Cholangiocarcinoma is a very aggressive cancer whose incidence is increasing. Moreover, chemotherapies are little effective and the response to immune checkpoint inhibitors is low. We have identified protein arginine-methyltransferase 5 (PRMT5) as a novel therapeutic target in cholangiocarcinoma. PRMT5-targeting drugs markedly inhibited CCA cells proliferation, synergizing with cisplatin and gemcitabine, and hindered the growth of cholangiocarcinoma organoids. PRMT5 inhibition blunted the expression of oncogenic genes involved in chromatin remodeling and DNA repair, consistently inducing the formation of RNA-loops and promoting DNA damage. Our findings support the evaluation of PRMT5 inhibitors in clinical trials.
Published in
Identification of PRMT5 as a therapeutic target in cholangiocarcinoma
Elurbide J, Colyn L, Latasa MU et al. · Gut 2024 · PMID 39266051 · doi:10.1136/gutjnl-2024-332998
This dataset
Download

Direct links to NCBI, no account and no request form: the whole study as GSE270017_RAW.tar, processed values as the series matrix, the supplementary file directory, and per-sample supplementary files for any of the 6 samples. Raw sequencing reads are also available from ENA.

Also filed as BioProject PRJNA1124869 and SRA study SRP514316. Searching any of these in the dataset finder brings you back here.

Samples in this study

The sample list for this study is not cached yet. Press Sort into groups and it will be fetched from NCBI.

+ 6 more — browse all 6 samples with per-sample file links →

Similar datasets

Search all human RNA-seq datasets in GEO →

Share this dataset

Metadata from NCBI GEO, cached and refreshed periodically — the NCBI page above is authoritative. Downloads link straight to NCBI/ENA; nothing is proxied through BioTransfer.